

AACR Special Conference on

Tumor Immunology and Immunotherapy

October 1-4, 2023 | Toronto, ON, Canada

AACR

American Association
for Cancer Research

2302036E

In association with the Cancer Immunology (CIMM) Working Group

COCHAIRS:

Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
Mario Sznol, Yale University, New Haven, CT

SUNDAY, OCTOBER 1

Registration

3:00 pm-8:00 pm | Metropolitan Ballroom Foyer

Welcome and Opening Keynote Lecture

6:30 pm-7:30 pm | Metropolitan Ballroom West

- 6:30-6:35 Welcome and Introduction of Keynote Speaker
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
- 6:35-7:15 Chasing T cell exhaustion
Crystal L. Mackall, Stanford University School of Medicine, Stanford, CA
- 7:15-7:30 Discussion / Q&A

Opening Reception

7:30 pm-9:30 pm | Metropolitan Ballroom East

MONDAY, OCTOBER 2

Continental Breakfast


7:00 am-8:00 am | Metropolitan Ballroom Centre

Plenary Session 1: T-cell Biology

Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 am-10:05 am | Metropolitan Ballroom West

- 8:00-8:05 Introduction
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
- 8:05-8:25 Critical role for Batf3-lineage dendritic cells within the tumor microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, IL
- 8:25-8:35 Discussion / Q&A



In association with the Cancer Immunology (CIMM) Working Group

- 8:35-8:55 Intratumoral CD4 T cells: Empowering CD8 T cells to eliminate tumors
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
- 8:55-9:05 Discussion / Q&A
- 9:05-9:25 Mechanisms of immunotherapy response and resistance in pancreatic cancer
Ingunn Stromnes, University of Minnesota Medical School, Minneapolis, MN
- 9:25-9:35 Discussion / Q&A
- 9:35-9:45 Regulation of exhausted CD8⁺ T cell differentiation by IKZF transcription factors
Sinead M. Reading, Peter MacCallum Cancer Centre, Melbourne, Australia *
- 9:45-9:50 Discussion / Q&A
- 9:50-10:05 Panel Discussion

Break


10:05 am-10:25 am | Metropolitan Ballroom Foyer

Plenary Session 2: Macrophages and Myeloid Cells

Session Chair: Jennifer L. Guerriero, Brigham and Women's Hospital, Boston, MA

10:25 am-12:30 pm | Metropolitan Ballroom West

- 10:25-10:30 Introduction
Jennifer L. Guerriero, Brigham and Women's Hospital, Boston, MA
- 10:30-10:50 Immune archetypes and the shifting paradigms of myeloid biology in cancer
Matthew F. Krummel, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
- 10:50-11:00 Discussion / Q&A
- 11:00-11:20 Decoding clinically distinct multicellular circuits and myeloid phenotypes in cancer
Aaron M. Newman, Stanford University, Stanford, CA
- 11:20-11:30 Discussion / Q&A
- 11:30-11:50 Unraveling the complexities of tumor associated macrophages for anti-cancer therapy of breast cancer
Jennifer L. Guerriero, Brigham and Women's Hospital, Boston, MA
- 11:50-12:00 Discussion / Q&A



In association with the Cancer Immunology (CIMM) Working Group

- 12:00-12:10 Lyn kinase regulates myeloid-cell responses to mammary tumors
Joseph T. Greene, Masonic Cancer Center University of Minnesota, Minneapolis, MN*
- 12:10-12:15 Discussion / Q&A
- 12:15-12:30 Panel Discussion

Lunch on Own / Free Time

12:30 pm-2:30 pm

Plenary Session 3: Inhibitory Cells

Session Chair: Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

2:30 pm-4:35 pm | Metropolitan Ballroom West


- 2:30-2:35 Introduction
Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
- 2:35-2:55 Hyperactivated CD4⁺ T cells lacking FoxP3 inhibit therapeutic tumor immunity
Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, MO
- 2:55-3:05 Discussion / Q&A
- 3:05-3:25 Inhibitory ILCs, B7-H3, and anti-tumor immunity
Pamela S. Ohashi, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
- 3:25-3:35 Discussion / Q&A
- 3:35-3:55 PMN-MDSC in regulation of immune suppressive microenvironment in cancer
Dmitry Gabrilovich, AstraZeneca, Philadelphia, PA
- 3:55-4:05 Discussion / Q&A
- 4:05-4:15 Hypoxia promotes inflammatory fibroblast formation in pancreatic cancer
Ashley M. Mello, University of Michigan, Ann Arbor, MI*
- 4:15-4:20 Discussion / Q&A
- 4:20-4:35 Panel Discussion

Poster Session A / Reception

4:45 pm-7:00 pm | Metropolitan Ballroom East

Evening off / Dinner on own

7:00 pm



AACR Special Conference on

Tumor Immunology and Immunotherapy

October 1-4, 2023 | Toronto, ON, Canada

AACR

American Association
for Cancer Research

2302036E

In association with the Cancer Immunology (CIMM) Working Group

TUESDAY, OCTOBER 3

Continental Breakfast

7:00 am-8:00 am | Metropolitan Ballroom Centre

Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity

Session Chair: Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, PA

8:00 am-10:05 am | Metropolitan Ballroom West

- | | |
|------------|--|
| 8:00-8:05 | Introduction Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, PA |
| 8:05-8:25 | Interferon modification of T cell function and response to immunotherapy David G. Brooks, University of Toronto, Toronto, ON, Canada |
| 8:25-8:35 | Discussion / Q&A |
| 8:35-8:55 | Metabolic and neural regulation of immunity and cancer Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada |
| 8:55-9:05 | Discussion / Q&A |
| 9:05-9:25 | LAG-3: The third checkpoint inhibitor & its synergistic interactions with PD1 Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, PA |
| 9:25-9:35 | Discussion / Q&A |
| 9:35-9:45 | Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity Lloyd Bod, Massachusetts General Hospital, Boston, MA* |
| 9:45-9:50 | Discussion / Q&A |
| 9:50-10:05 | Panel Discussion |

Break


10:05 am-10:25 am | Metropolitan Ballroom Foyer

Plenary Session 5: Metabolic Modulation of Anti-tumor Immunity

Session Chair: Greg M. Delgoffe, UPMC Hillman Cancer Center, Pittsburgh, PA

10:25 am-12:30 pm | Metropolitan Ballroom West

- | | |
|-------------|--|
| 10:25-10:30 | Introduction Greg M. Delgoffe, UPMC Hillman Cancer Center, Pittsburgh, PA |
|-------------|--|



In association with the Cancer Immunology (CIMM) Working Group

- 10:30-10:50 Metabolic modulation during in vitro expansion for curative adoptive cell therapy for cancer
Greg M. Delgoffe, UPMC Hillman Cancer Center, Pittsburgh, PA
- 10:50-11:00 Discussion / Q&A
- 11:00-11:20 Obesity and immunometabolism in cancer immunotherapy
Jeffrey Rathmell, Vanderbilt University Medical Center, Nashville, TN
- 11:20-11:30 Discussion / Q&A
- 11:30-11:50 Tailoring T cell anti-tumor immunity via reprogramming mitochondria-guided transcription networks
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland
- 11:50-12:00 Discussion / Q&A
- 12:00-12:10 Dgat1 camouflages sexual dimorphism in anti-tumor CD8+ T cell immunity
Alaa Madi, German Cancer Research Center, Heidelberg, Germany*
- 12:10-12:15 Discussion / Q&A
- 12:15-12:30 Panel Discussion

Lunch on Own / Free Time


12:30 pm-2:30 pm

Plenary Session 6: TCR-targeted Immunotherapies

Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

2:30 pm-4:35 pm | Metropolitan Ballroom West

- 2:30-2:35 Introduction
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA
- 2:35-2:55 T-cell specificity, phenotype, and dynamics: Impact on cancer immunotherapy
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA
- 2:55-3:05 Discussion / Q&A
- 3:05-3:25 Cancer neoantigens: From discovery to the clinic
Nina Bhardwaj, The Tisch Cancer Institute, New York, NY
- 3:25-3:35 Discussion / Q&A
- 3:35-3:55 Specificity matters: The breadth of endogenous and elicited anti-tumor T cell responses
Paul G. Thomas, St. Jude Children's Research Hospital, Memphis, TN
- 3:55-4:05 Discussion / Q&A



AACR Special Conference on

Tumor Immunology and Immunotherapy

October 1-4, 2023 | Toronto, ON, Canada

AACR
American Association
for Cancer Research

2302036E

In association with the Cancer Immunology (CIMM) Working Group

- 4:05-4:15 Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division
Mary Philip, Vanderbilt University Medical Center, Nashville, TN*
- 4:15-4:20 Discussion / Q&A
- 4:20-4:35 Panel Discussion

Poster Session B / Reception

4:45 pm-7:00 pm | Metropolitan Ballroom East

Evening off / Dinner on own

7:00 pm

WEDNESDAY, OCTOBER 4

Continental Breakfast


7:00 am-8:00 am | Metropolitan Ballroom Centre

Plenary Session 7: Spatial Profiling

Session Chair: Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, NY

8:00 am-9:50 am | Metropolitan Ballroom West

- 8:00-8:05 Introduction
Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, NY
- 8:05-8:25 Identifying regulators of tumor immunity by spatial functional genomics
Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, NY
- 8:25-8:35 Discussion / Q&A
- 8:35-8:55 Recirculating tumor-specific T cell responses as biomarkers for virally driven cancers
Evan Newell, Fred Hutchinson Cancer Research Center, Seattle, WA
- 8:55-9:05 Discussion / Q&A
- 9:05-9:15 Communication is key: Understanding the modulating effect of immune cell crosstalk on T cell therapy function*
Amber K.L. Wezenaar, Princess Maxima Center, Utrecht, Netherlands
- 9:15-9:20 Discussion / Q&A
- 9:20-9:50 Panel Discussion



AACR Special Conference on

Tumor Immunology and Immunotherapy

October 1-4, 2023 | Toronto, ON, Canada

AACR
American Association
for Cancer Research

2302036E

In association with the Cancer Immunology (CIMM) Working Group

Break

9:50 am-10:05 am | Metropolitan Ballroom Foyer

Plenary Session 8: Synthetic Biology and Immune Cell Engineering

Session Chair: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

10:05 am-11:55 am | Metropolitan Ballroom West

- 10:05-10:10 Introduction
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
- 10:10-10:30 Gene deletions unveiled: Cracking the code for CAR T cell supremacy
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
- 10:30-10:40 Discussion / Q&A
- 10:40-11:00 'Ain't no mountain high enough': Making TCR-T cells work against solid tumors
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
- 11:00-11:10 Discussion / Q&A
- 11:10-11:30 Antigen sensitivity and functional persistence of CAR T cells
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
- 11:30-11:40 Discussion / Q&A
- 11:40-11:55 Panel Discussion

Break


11:55 am-12:10 pm | Metropolitan Ballroom Foyer

Plenary Session 9: Engineered Cytokines

Session Chair: Mario Sznol, Yale University, New Haven, CT

12:10 pm-2:00 pm | Metropolitan Ballroom West

- 12:10-12:15 Introduction
Mario Sznol, Yale University, New Haven, CT
- 12:15-12:35 PD1-IL2v: PD-1-Cis IL-2R β agonism yields better T cell effectors from stem-like CD8+ T cells
Pablo Umana, Roche, Schlieren, Switzerland
- 12:35-12:45 Discussion / Q&A



AACR Special Conference on

Tumor Immunology and Immunotherapy

October 1-4, 2023 | Toronto, ON, Canada

AACR
American Association
for Cancer Research

2302036E

In association with the Cancer Immunology (CImm) Working Group

- 12:45-1:05 Restricting the activity of IL-2 and IL-21 to CD8+ T cells greatly enhances their therapeutic potential
Ivana Djuretic, Asher Biotherapeutics, Inc., South San Francisco, CA
- 1:05-1:15 Discussion / Q&A
- 1:15-1:35 Challenges in cancer immunotherapy: Connecting the solutions to the problems
Mario Sznol, Yale University, New Haven, CT
- 1:35-1:45 Discussion / Q&A
- 1:45-2:00 Panel Discussion

Closing Comments and Departure

2:00 pm | Metropolitan Ballroom West

Mario Sznol, Yale University, New Haven, CT

** - Short talk selected from proffered abstract*